Plain-English translation of NCT07012954 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing two different treatment approaches for people with advanced colorectal cancer that has progressed despite earlier therapies. One approach combines cetuximab with , while the other combines bevacizumab with the same chemotherapy drug. The study uses a blood test to identify which patients are most likely to benefit from the medication.
Some colorectal cancer patients respond well to certain targeted therapies initially, but then the cancer progresses. Recent research suggests that using the same type of targeted therapy again later—guided by genetic testing—may help some patients. This trial is comparing two different strategies to see which approach works better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two treatment combinations. Both involve taking an oral chemotherapy pill for 5 days followed by 9 days off, paired with an intravenous infusion every two weeks. You will have regular clinic visits for blood tests, scans, and check-ups to monitor how the treatment is working and manage any side effects. The trial continues until your cancer progresses, you experience unacceptable side effects, or the study ends.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China